VO-Ohpic trihydrate

Catalog No.S8174 Batch:S817402

Print

Technical Data

Formula

C12H9N2O8V.3H2O.H
Molecular Weight 415.20 CAS No. 476310-60-8
Solubility (25°C)* In vitro DMSO 83 mg/mL (199.9 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description VO-Ohpic is a potent inhibitor of PTEN (phosphatase and tensin homolog) with IC50 of 35 nM.
Targets
PTEN
(Cell-free assay)
35 nM
In vitro VO-OHpic is a potent small-molecule compound that specifically inhibits PTEN’s cellular enzymatic activity, which in turn activates downstream targets such as Akt and FoxO3a. Glucose uptake into adipocytes is dramatically enhanced upon PTEN inhibition with VO-OHpic. PTEN inhibitor accelerates wound healing in fibroblasts. VO-OHpic inhibits cell viability, cell proliferation and colony formation, and induces senescence-associated β-galactosidase activity in Hep3B (low PTEN expression) and to a lesser extent in PLC/PRF/5 (high PTEN expression) cells, but not in PTEN-negative SNU475 cells.
In Vivo VO-Ohpic significantly inhibits tumour growth in nude mice bearing xenografts of Hep3B cells. VO-Ohpic administered to C57BL6 mice 30 minutes prior to Kcl-induced asystolic cardiac arrest significantly increases survival, LVPmax and dP/dt max with continued benefit. VO-OHpic also significantly increases lactate clearance and decreases plasma glucose level.

Protocol (from reference)

Cell Assay:[2]
  • Cell Lines

    The human hepatocellular carcinoma cell lines Hep3B, PLC/PRF/5, and SNU475

  • Concentrations

    0-5 μM

  • Incubation Time

    72 h

  • Method

    Cell proliferation is determined by estimating the amount of bromodeoxyuridine (BrdU) incorporation into DNA by a colorimetric immunoassay. 3×103 cells are cultured in 96-well plates with varying concentrations of VO-OHpic for 72 hours. BrdU is added 24 hours before the end of the treatments. Results are expressed as the percentage inhibition of BrdU incorporation over the control.
Animal Study:[2]
  • Animal Models

    Male nude athymic mice

  • Dosages

    10 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/17240976/
  • https://pubmed.ncbi.nlm.nih.gov/26794644/
  • http://www.exhibitatsessions.org/wp-content/uploads/2014/02/aha_day2_2013.pdf

Sellecks VO-Ohpic trihydrate Has Been Cited by 10 Publications

T cell receptor associated transmembrane adaptor 1 (TRAT1) modulates human Th17 and Treg responses via PI3-kinase and STAT dependent mechanisms [ Cell Commun Signal, 2025, 23(1):431] PubMed: 41074026
In vitro reconstitution of epigenetic reprogramming in the human germ line [ Nature, 2024, 631(8019):170-178] PubMed: 38768632
PTEN inhibitor VO-OHpic protects endplate chondrocytes against apoptosis and calcification via activating Nrf-2 signaling pathway [ Aging (Albany NY), 2023, 15(6):2275-2292] PubMed: 36971687
Cardiac-specific Knockdown of DEC1 Regulated Pressure Overload-induced Cardiac Hypertrophy and Remodeling by Directly Inhibiting the Expression of PTEN [ Research Square, 2023, Version 1] PubMed: None
PTEN inhibitor VO-OHpic attenuates GC-associated endothelial progenitor cell dysfunction and osteonecrosis of the femoral head via activating Nrf2 signaling and inhibiting mitochondrial apoptosis pathway. [ Stem Cell Res Ther, 2020, 11(1):140] PubMed: 32228695
MiR-455-3p reduces apoptosis and alleviates degeneration of chondrocyte through regulating PI3K/AKT pathway. [ Life Sci, 2020, 25;253:117718] PubMed: 32343998
Gallic Acid Ameliorates Angiotensin II-Induced Atrial Fibrillation by Inhibiting Immunoproteasome- Mediated PTEN Degradation in Mice [ Front Cell Dev Biol, 2020, 8:594683] PubMed: 33251220
MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. [ Aging (Albany NY), 2020, 24;12(2):1213-1236] PubMed: 31981455
VO-OHpic Attenuates Intervertebral Disc Degeneration via PTEN/Akt Pathway [ Eur Rev Med Pharmacol Sci, 2020, 24(6):2811-2819] PubMed: 32271398
SHIP2 inhibition alters redox-induced PI3K/AKT and MAP kinase pathways via PTEN over-activation in cervical cancer cells [ FEBS Open Bio, 2020, 10(10):2191-2205] PubMed: 32881386

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.